Omeros (NASDAQ:OMER) Reaches New 1-Year High – What’s Next?

Omeros Co. (NASDAQ:OMER) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $13.60 and last traded at $10.24, with a volume of 5997596 shares traded. The stock had previously closed at $7.46.

Analysts Set New Price Targets

A number of research firms recently commented on OMER. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Rodman & Renshaw assumed coverage on Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective on the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Thursday. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Omeros Trading Up 0.7 %

The stock has a 50-day simple moving average of $7.09 and a 200 day simple moving average of $5.19. The stock has a market capitalization of $597.46 million, a price-to-earnings ratio of -4.46 and a beta of 1.97.

Institutional Investors Weigh In On Omeros

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its stake in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares in the last quarter. MML Investors Services LLC lifted its holdings in Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the last quarter. SPC Financial Inc. acquired a new position in Omeros during the third quarter valued at approximately $77,000. SG Americas Securities LLC bought a new position in shares of Omeros in the third quarter valued at approximately $80,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Omeros in the second quarter worth $105,000. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.